Page 8 - Metastatic castration-naive and castration-sensitive prostate cancer: CUA/CUOG

Systemic therapies: Chemotherapy

2
• Docetaxel (75 mg/m every three weeks for six cycles) plus ADT is an
option for men with good performance status and high-volume metastatic

disease (Level 1, Strong recommendation)

• Docetaxel plus ADT may also be an option in patients with good

performance status with low-volume disease (Level 2, Weak

recommendation)

• “High-risk” patients with good performance status can also be considered

for docetaxel chemotherapy (Level 1, Strong recommendation)

ADT: androgen-deprivation therapy